An expression of the live unlimited spirit, stories and voices of the MDA community
Researchers are looking for people to participate in a clinical trial, sponsored by Cedars-Sinai Medical Center, to test the safety and efficacy of beetroot juice extract in people with BMD.
Researchers are looking for people to participate in a phase 2 clinical trial, sponsored by Neuraltus Pharmaceuticals, that is designed to test whether the investigational drug NP001 slows progression of signs and symptoms in ALS.
This week, hundreds of the best and brightest scientists from around the country are gathering in the Washington, D.C., area at the 2017 MDA Scientific Conference, with the goal of working collectively toward advancing scientific breakthroughs to save and improve lives for MDA families.
New research, supported by MDA and the CMT Association, examines gene therapy in CMT.
PTC Therapeutics reached an agreement with Marathon Pharmaceuticals to acquire all rights to Emflaza™ (deflazacort), the first treatment approved in the U.S. for all Duchenne muscular dystrophy (DMD) patients five years and older, regardless of their genetic mutation.
Meet Shamrockstar Henry, whose positive attitude stems from his family’s optimism about potential treatments and cures for Duchenne muscular dystrophy.
Learn why five MDA families are equally dedicated to Muscle Walk — and why you should also support this incredible cause.
Twin sisters Avery and Kennedy from California were diagnosed with spinal muscular atrophy (SMA) type 2 when they were infants. Now, they are featured on MDA Shamrocks available at Lowe’s Home Improvement across the country this year. They love being involved with the Shamrocks program because it helps fund their favorite part of MDA: dance parties at summer camp!
Alexion Pharma announced the FDA will review its investigational drug eculizumab (brand name Soliris) for treatment of refractory generalized MG.
MDA has awarded an MDA Venture Philanthropy (MVP) grant to Izumi Biosciences, Inc., to fund early-stage development of IZ10023, for use in people with ALS who are taking riluzole, the only drug approved by the U.S. Food and Drug Administration to treat ALS.
Sign up for MDA news & updates.
